UTR Therapeutics Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to 3′UTRMYCN M1-14 (UTRxMYCN M1-14) for the treatment of soft tissue sarcoma, including rhabdomyosarcoma (RMS), and Rare Pediatric Disease Designation (RPDD) for the treatment of RMS.
The company’s core technology of ultra-targeted 3′UTR engineering, invented by Chidiebere U. Awah, CEO of UTR Therapeutics, targets the oncogenic mRNA of undruggable genes, overwrites their endogenous oncogenic mRNA messages, and triggers them for degradation by the nonsense-mediated decay pathway, thus eliminating the diseased mRNA while sparing the healthy mRNA.
MYCN (N-MYC) is a basic helix-loop-helix transcription factor belonging to the MYC superfamily. It is an intrinsically disordered transcription factor with no binding pocket, which has rendered it “undruggable” and beyond the reach of conventional methods.
MYCN is a defining oncogenic driver of aggressive soft tissue sarcomas, including fusion-positive rhabdomyosarcoma, the most common soft tissue sarcoma in children. MYCN contributes to a subset of the more than 80 soft tissue sarcoma subtypes affecting children and adults. There are currently no clinically approved therapies that directly target MYCN.
In preclinical studies, UTRxMYCN M1-14, invented by Awah, reliably targeted and degraded the oncogenic MYCN in aggressive MYCN-driven rhabdomyosarcoma, including the deadly fusion-positive rhabdomyosarcoma. The drug achieved on-target specificity and therapeutic efficacy, demonstrating dose-dependent inhibition of MYCN, tumour inhibition, and inhibition of liver and lung metastasis while remaining safe.
“The ODD and RPDD designations granted to UTRxMYCN M1-14 by the U.S. FDA validate the UTR Therapeutics platform technology and the potential of UTRxMYCN M1-14 to address several aggressive sarcomas that represent serious unmet needs in the U.S. and worldwide,” said David T. Asuzu, chief medical officer.